imatinib for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

Covid-19 HUF, 2021 NCT04346147

imatinib vs. lopinavir/ritonavir plus chloroquine

COVID-19 mild to moderate

Aman, 2021 Eudra 2020–001236–10

imatinib vs. placebo

COVID-19 severe or critically

COUNTER-COVID, 0 2020-001236-10

imatinib vs. placebo

COVID-19 severe or critically

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open